F 598

Drug Profile

F 598

Alternative Names: F598; SAR279356

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alopexx Pharmaceuticals
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Surface antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bacterial infections

Most Recent Events

  • 07 Jul 2017 Alopexx Pharmaceuticals plans a phase II trial for Neisseria Gonorrhoeae (Prevention, In volunteers) in USA (IV) (NCT03222401)
  • 11 Apr 2016 Phase-II development is ongoing in USA
  • 07 Feb 2013 Phase-II development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top